| 產(chǎn)品編號(hào) | BIO0847SM |
| 英文名稱(chēng) | Anti-human TSLP (Tezepelumab Biosimilar) |
| 中文名稱(chēng) | |
| 抗體來(lái)源 | |
| 克隆類(lèi)型 | Monoclonal |
| 交叉反應(yīng) | Human,Cynomolgus |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 144.6 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG2SA |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Tezepelumab reduced levels of IL13 in BALF of OVA asthma model on B-hTSLP/hTSLPR mice. The result showed significant IL13 inhibition effects at 15 mpk.
Anti-TSLP Reference Antibody (tezepelumab)-induced FACS Blocking activity was evaluated using TSLPR/IL7R-CHO-K. The IC50 was approximately 0.0802 ug/mL.
Immobilized human TSLP His at 2 ug/mL can bind Anti-TSLP Reference Antibody (tezepelumab), EC50=0.0518 ug/mL.
The purity of Anti-TSLP Reference Antibody (tezepelumab) is 98.64%, determined by SEC-HPLC.
Anti-TSLP Reference Antibody (tezepelumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
